NBTX Nanobiotix S.A. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1760854 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 32.59M | -7.19M | 36.21M | 4.78M | 2.65M |
| R&D expense | 23.11M | 40.54M | 38.40M | 32.64M | 30.38M |
| SG&A expense | 20.36M | 20.53M | 22.05M | 17.86M | 19.43M |
| Operating income | -10.82M | -68.39M | -26.78M | -46.70M | -52.58M |
| Interest expense | 15.23M | 7.49M | 14.80M | 13.86M | 780,000 |
| Pretax income | -23.96M | -68.13M | -39.70M | -57.04M | -47.00M |
| Income tax | 3,000 | 101,000 | 120,000 | 10,000 | 5,000 |
| Net income | -23.96M | -68.13M | -39.70M | -57.04M | -47.06M |
| EBITDA | -9.32M | -66.77M | -25.27M | -45.20M | -51.02M |
| EPS (basic) | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 |
| EPS (diluted) | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 |
| Banking | |||||
| Net interest income | -10.27M | -7.92M | -7.78M | -5.60M | -383,000 |
| Balance sheet | |||||
| Cash & equivalents | 52.75M | 49.74M | 75.28M | 41.39M | 83.92M |
| Receivables | 2.14M | 2.98M | 905,000 | 101,000 | 0 |
| Current assets | 62.75M | 61.47M | 87.34M | 52.36M | 93.06M |
| PP&E, netmay include right-of-use assets (IFRS) | 4.57M | 5.54M | 6.25M | 7.12M | 8.19M |
| Intangibles | 10,000 | 7,000 | 8,000 | 1,000 | 4,000 |
| Total assets | 67.76M | 67.42M | 93.90M | 59.77M | 101.77M |
| Current liabilities | 57.51M | 58.94M | 49.87M | 37.94M | 36.84M |
| Total liabilities | 152.24M | 133.12M | 95.74M | 86.81M | 74.98M |
| Shareholders' equity | -84.48M | -65.70M | -1.84M | -27.05M | 26.79M |
| Cash flow statement | |||||
| Operating cash flow | -33.42M | -19.55M | -12.48M | -37.10M | -29.87M |
| Capital expenditure | 538,000 | 846,000 | 328,000 | 92,000 | 228,000 |
| Free cash flow | -33.96M | -20.40M | -12.80M | -37.20M | -30.10M |
| Investing cash flow | -578,000 | -955,000 | -349,000 | 138,000 | -242,000 |
| Financing cash flow | 37.42M | -5.13M | 46.77M | -5.65M | -5.18M |
| Depreciation & amortization | 1.50M | 1.62M | 1.51M | 1.50M | 1.56M |
| Stock-based compensation | 3.54M | 4.30M | 3.22M | 3.17M | 3.20M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.